Patients With Aberrations in Two Genes Respond Better to Drugs Blocking a Well-Known Cancer Pathway, MD Anderson Cancer Center Study  
11/8/2012 7:32:58 AM

Cancer patients with mutations or variations in two genes -– PIK3CA and PTEN -– who have failed to respond to several, standard treatments, respond significantly better to anti-cancer drugs that inhibit these genes' pathways of action, according to research presented at the 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Dublin, Ireland, today.